FIELD: biochemistry.
SUBSTANCE: invention relates to biochemistry, particularly, to bispecific bivalent antibody, which is specifically bound to human vascular endothelial growth factor (VEGF) and human angiopoietin-2 (ANG-2). Invention also discloses: a pharmaceutical composition for treating cancer related to the VEGF and ANG-2 containing a therapeutically effective amount of the said bispecific antibody, nucleic acid coding the said antibody, an expression vector containing the said nucleic acid, prokaryotic or eukaryotic host cell containing the said vector. Disclosed is a method of producing the said bispecific antibody.
EFFECT: invention provides effective treatment of VEGF- and ANG-2-mediated cancer.
9 cl, 15 dwg, 11 tbl, 13 ex
Title | Year | Author | Number |
---|---|---|---|
BISPECIFIC ANTI-VEGF/ANTI-ANG-2 ANTIBODIES | 2009 |
|
RU2542382C2 |
BISPECIFIC ANTI-VEGF/ANTI-ANG-2 ANTIBODIES | 2014 |
|
RU2640253C2 |
ANTIBODIES AGAINST HUMAN ANGIOPOIETIN-2 | 2009 |
|
RU2569461C2 |
ANTIBODIES AGAINST HUMAN ANGIOPOIETIN-2 | 2009 |
|
RU2569107C2 |
BISPECIFIC ANTIBODIES | 2011 |
|
RU2573588C2 |
Fc-RECEPTOR BINDING MODIFIED ASYMMETRIC ANTIBODIES AND METHODS OF USE | 2014 |
|
RU2687043C2 |
BISPECIFIC, TETRAVALENT ANTIGEN BINDING PROTEINS | 2010 |
|
RU2604189C2 |
COMPOSITION CONTAINING ANTIBODY | 2019 |
|
RU2806628C2 |
BISPECIFIC ANTIGEN-BINDING PROTEINS | 2010 |
|
RU2573914C2 |
BISPECIFIC ANTI-HER2 / ANTI-HER3 ANTIBODIES | 2016 |
|
RU2653443C2 |
Authors
Dates
2016-09-20—Published
2011-03-24—Filed